No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 80.5x · 10Y median 39.7x · 71st percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:26.647Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Aclarion, Inc. (ACON) stock was $2.34 as of Oct 5, 2026, 4:00 PM EDT, down 1.68% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -68.0% · 3-year avg -96.6%/yr
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications.
Medical - Healthcare Information Services · Broomfield, CA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-1.05
Revenue Est.
$40000.00
Last Quarter Results
EPS
$-1.12
vs Estimate
$-1.05
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ACON | $6.74M | $2.34 | -1.68% | -68.01% | N/A | N/A | N/A |
| 2ENVB | $6.76M | $1.51 | +2.03% | N/A | N/A | N/A | vs ACON |
| 3BOLT | $6.72M | $3.50 | +1.42% | -33.96% | -57.61% | N/A | vs ACON |
| 4CODX | $6.88M | $1.10 | +1.85% | -90.34% | -66.53% | N/A | vs ACON |
| 5KALA | $7.01M | $0.36 | -5.84% | -99.52% | -85.73% | N/A | vs ACON |
| 6CURX | $7.03M | $4.96 | +5.08% | -68.03% | N/A | N/A | vs ACON |
N/A
$25208.00
vs Estimate
$30000.00
Consensus Rating
Based on 2 analysts
Average Price Target
$7.63
+225.9% upside
Low
$7.50
Current
$2.34
High
$7.75
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.05 | $-1.05 | $-1.05 | 1 |
| Quarter ending Dec 2026 | $-1.09 | $-1.09 | $-1.09 | 1 |
| Quarter ending Mar 2027 | $-1.51 | $-1.51 | $-1.51 | 1 |
| Quarter ending Jun 2027 | $-1.30 | $-1.30 | $-1.30 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.51 | $-4.51 | $-4.51 | 1 |
| FY 2027 | $-5.37 | $-5.37 | $-5.37 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $40000.00 | $40000.00 | $40000.00 | 1 |
| Quarter ending Dec 2026 | $50000.00 | $50000.00 | $50000.00 | 1 |
| Quarter ending Mar 2027 | $40000.00 | $40000.00 | $40000.00 | 1 |
| Quarter ending Jun 2027 | $60000.00 | $60000.00 | $60000.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $140000.00 | $140000.00 | $140000.00 | 1 |
| FY 2027 | $260000.00 | $260000.00 | $260000.00 | 1 |
